Mutations of Ras, MEK and AKT were shown to antagonize JAK2 inhibition in MPN model cell lines, while combinational treatment approaches, such as the inhibition of AKT and MEK were able to reduce the IC50 of JAK2 inhibitors. The gene discussed is AKT1; the disease is myeloproliferative disorder.